Neonatal Abstinence Syndrome: An Update on the Cost and Length of Stay Associated with Treatment during the Hospital Stay

Authors

Kimberly Stanfield, Marshall University
Kylie Day, Marshall University
Sarah M. Clemente, Marshall University
Alberto Coustasse, Marshall UniversityFollow

Document Type

Article

Publication Date

3-24-2023

Abstract

Neonatal Abstinence Syndrome (NAS) has been costly for the healthcare system; every 19 minutes, a newborn was diagnosed in 2021. Medically Assisted Treatment (MAT)) for expecting mothers has been shown to decrease costs and length of stay for newborns NAS. This study utilized a literature review and a semi-structured interview. The research showed that medically assisted treatment with methadone or buprenorphine during pregnancy decreased costs, LOS, and severity of symptoms for newborns diagnosed with NAS. The findings showed a positive association between lower costs for the initial stay of infants whose mothers received MAT. MAT during pregnancy has been shown to correlate positively with a shorter initial LOS for infants with NAS.

Comments

This is the authors’ manuscript of a presentation given at MBAA International https://mbaainternational.org/. Copyright © 2023 The Authors. All rights reserved.

Recommended Citation

Stanfield, K., Day, K., Clemente, S. M. Coustasse, A. (2023, March 24). “Neonatal Abstinence Syndrome: An Update on the Cost and Length of Stay Associated with Treatment during the Hospital Stay.” Presented at MBAA International, Chicago, IL.